liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Does Heterogeneity Exist in Treatment Associations With Renin–Angiotensin–System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands; Amsterdam University Medical Centers, Department of Cardiology, University of Amsterdam, Amsterdam, the Netherlands; Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID iD: 0000-0003-2835-7741
Department of Cardiology, Groene Hart Ziekenhuis, Gouda, the Netherlands.
Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Division of Cardiology, Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Trieste, Italy.
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart Center, Department of Cardiology in Linköping.ORCID iD: 0000-0001-6353-8041
Show others and affiliations
2024 (English)In: Journal of Cardiac Failure, ISSN 1071-9164, E-ISSN 1532-8414, Vol. 30, no 4, p. 541-551Article in journal (Refereed) Published
Abstract [en]

Background

We explored the association between use of renin–angiotensin system inhibitors and beta-blockers, with mortality/morbidity in 5 previously identified clusters of patients with heart failure with preserved ejection fraction (HFpEF).

Methods and Results

We analyzed 20,980 patients with HFpEF from the Swedish HF registry, phenotyped into young–low comorbidity burden (12%), atrial fibrillation–hypertensive (32%), older–atrial fibrillation (24%), obese–diabetic (15%), and a cardiorenal cluster (17%). In Cox proportional hazard models with inverse probability weighting, there was no heterogeneity in the association between renin–angiotensin system inhibitor use and cluster membership for any of the outcomes: cardiovascular (CV) mortality, all-cause mortality, HF hospitalisation, CV hospitalisation, or non-CV hospitalisation. In contrast, we found a statistical interaction between beta-blocker use and cluster membership for all-cause mortality (P = .03) and non-CV hospitalisation (P = .001). In the young–low comorbidity burden and atrial fibrillation–hypertensive cluster, beta-blocker use was associated with statistically significant lower all-cause mortality and non-CV hospitalisation and in the obese–diabetic cluster beta-blocker use was only associated with a statistically significant lower non-CV hospitalisation. The interaction between beta-blocker use and cluster membership for all-cause mortality could potentially be driven by patients with improved EF. However, patient numbers were diminished when excluding those with improved EF and the direction of the associations remained similar.

Conclusions

In patients with HFpEF, the association with all-cause mortality and non-CV hospitalisation was heterogeneous across clusters for beta-blockers. It remains to be elucidated how heterogeneity in HFpEF could influence personalized medicine and future clinical trial design.

Graphical abstract

AF = atrial fibrillation; CI = % confidence interval; CV = cardiovascular; DM = diabetes; HF = heart failure; HFpEF = Heart failure with preserved ejection fraction; HR = hazard ratio; HT = hypertension; RAS = renin–angiotensin system.

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 30, no 4, p. 541-551
Keywords [en]
Phenotype clusters, personalized medicine, HFpEF, renin–angiotensin system inhibitors, beta-blockers
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:liu:diva-212146DOI: 10.1016/j.cardfail.2023.08.008ISI: 001227352700001Scopus ID: 2-s2.0-85171560029OAI: oai:DiVA.org:liu-212146DiVA, id: diva2:1942681
Note

This work was supported by the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant n° 116074. F. W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. I. Vaartjes is supported by the Dutch Heart Foundation, as part of “Facts and Figures.”

Available from: 2025-03-06 Created: 2025-03-06 Last updated: 2025-03-06Bibliographically approved

Open Access in DiVA

fulltext(1123 kB)69 downloads
File information
File name FULLTEXT01.pdfFile size 1123 kBChecksum SHA-512
6e340313285f6443c8a18f98096707721396038d1b673082848e5a0fa5aa7ffb91243c559ccd2e1326191c34d31016351ea7adcfff89467d0ab72e0741bcac6c
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Dahlström, Ulf

Search in DiVA

By author/editor
Uijl, AliciaDahlström, Ulf
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health SciencesDepartment of Cardiology in Linköping
In the same journal
Journal of Cardiac Failure
Cardiology and Cardiovascular Disease

Search outside of DiVA

GoogleGoogle Scholar
Total: 70 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 790 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf